Opportunity Information: Apply for RFA HL 12 021
Apply for RFA HL 12 021
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Pulmonary Vascular Right Ventricular Axis Research Program (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.837 Cardiovascular Diseases Research 93.838 Lung Diseases Research.
- This funding opportunity was created on Apr 5, 2011 and posted on Apr 5, 2011.
- Applicants must submit their applications by Oct 13, 2011. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,050,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: Native American tribal governments (Federally recognized) Special district governments Others (see text field entitled Additional Information on Eligibility for clarification) State governments Private institutions of higher education County governments Small businesses Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Foreign (non U.S.) components of U.S. Organizations are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Pulmonary Vascular Right Ventricular Axis Research Program (R01) is a National Institutes of Health (NIH) funding opportunity designed to support research focused on right ventricular (RV) function, dysfunction, and disease, with particular emphasis on how the RV interacts with pulmonary vascular disease. The core idea behind this program is that outcomes in conditions like pulmonary hypertension and other lung vascular disorders are often driven not only by the pulmonary vessels themselves, but also by how the right side of the heart adapts or fails under increased pressure and vascular resistance. Through this FOA, NIH is seeking projects that can move the field toward better ways to detect RV disease earlier, understand its mechanisms more clearly, and ultimately develop improved diagnostics and therapeutics that target RV pathology in the context of pulmonary vascular disease.
A defining feature of the program is its expectation of a multidisciplinary and collaborative team science approach. Applicants are strongly encouraged to use the multiple principal investigator (multiple PI) model, which signals that NIH anticipates complex, cross-cutting projects that may span cardiology, pulmonology, vascular biology, imaging, physiology, bioengineering, genomics, biomarker discovery, clinical trial methods, and related fields. The emphasis on the "right ventricular pulmonary vascular axis" also suggests that proposed studies should not treat RV failure as an isolated cardiac problem, but should instead consider the coupled relationship between the pulmonary circulation and RV structure and function, including how changes in one compartment drive remodeling and dysfunction in the other.
Unlike many preclinical initiatives, this FOA explicitly requires human subjects research to be proposed. That requirement makes the program particularly oriented toward clinically grounded investigation, such as studies that incorporate patient cohorts, clinical phenotyping, advanced imaging, invasive or noninvasive hemodynamics, human-derived specimens, biomarker validation, or translational approaches that directly evaluate relevance in people. Applicants would therefore need to align their plans with NIH human subjects policies and be prepared to address protections, study design, recruitment, and other regulatory and ethical considerations typical of patient-oriented research.
The mechanism is an R01 research project grant, categorized under Health, and associated with CFDA numbers 93.837 (Cardiovascular Diseases Research) and 93.838 (Lung Diseases Research). The opportunity was posted on April 5, 2011, with an original and current closing date of October 13, 2011, and it was archived on November 13, 2011. The estimated total funding level listed for the program is $4,050,000, with an award ceiling of $450,000, and there is no cost sharing or matching requirement. In practical terms, this indicates a defined pool intended to support several awards, with a cap on the maximum size of any single award under the announcement.
Eligibility is broad and spans a wide range of organizations. Eligible applicants include federal, state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofits both with and without 501(c)(3) status (including those other than institutions of higher education); for-profit organizations (including small businesses as well as other for-profit entities); and public housing authorities/Indian housing authorities. The FOA also specifies additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and certain tribal organizations and governments, including those not federally recognized in some categories. Importantly, the announcement allows non-U.S. entities (foreign organizations) to apply, and it also allows foreign components of U.S. organizations, which opens the door to international collaboration or recruitment, provided the project fits NIH rules and the FOA requirements.
Overall, this NIH R01 program is aimed at accelerating progress in an area where clinical need is high: understanding and treating RV dysfunction and failure that arise in pulmonary vascular disease. By requiring human subjects research and encouraging multi-PI, team-based projects, the FOA is structured to promote clinically meaningful, translational work that can connect mechanistic insights to real-world diagnostic and therapeutic advances. For the full official announcement and any detailed requirements or instructions beyond the summary, the source link provided is the NIH Grants Guide page for RFA-HL-12-021.
Frequently Asked Questions (FAQs)
What is the Pulmonary Vascular Right Ventricular Axis Research Program (R01)?
It is a National Institutes of Health (NIH) funding opportunity that supports research on right ventricular (RV) function, dysfunction, and disease, with a specific focus on how the RV interacts with pulmonary vascular disease. The program emphasizes the idea that outcomes in pulmonary hypertension and related lung vascular disorders are strongly influenced by how the right side of the heart adapts (or fails) in response to increased pulmonary pressure and vascular resistance.
What scientific focus is NIH looking for under this opportunity?
Projects are expected to advance earlier detection of RV disease, improve understanding of RV mechanisms, and support development of better diagnostics and therapeutics that target RV pathology in the context of pulmonary vascular disease. A key theme is the coupled relationship between the pulmonary circulation and RV structure/function (the "right ventricular pulmonary vascular axis").
Does this program treat RV failure as a standalone cardiac problem?
No. The opportunity specifically encourages studies that consider RV failure and pulmonary vascular disease as linked, interacting processes. Proposed work should address how changes in the pulmonary vasculature influence RV remodeling and dysfunction, and how RV changes may relate back to pulmonary vascular disease.
Is a multidisciplinary or team science approach expected?
Yes. The program highlights multidisciplinary, collaborative team science as a defining feature. The expected scope may span areas such as cardiology, pulmonology, vascular biology, imaging, physiology, bioengineering, genomics, biomarker discovery, and clinical trial methods.
Is the multiple principal investigator (multiple PI) model required?
The opportunity strongly encourages use of the multiple PI model. This signals that NIH anticipates complex projects that benefit from shared leadership across disciplines, although the summary indicates encouragement rather than stating it is mandatory.
Are human subjects required for proposed research?
Yes. Unlike many preclinical initiatives, this funding opportunity explicitly requires that applicants propose human subjects research. This positions the program toward clinically grounded and translational investigation directly involving people.
What kinds of human subjects activities fit the intent of this FOA?
Examples described include studies with patient cohorts, clinical phenotyping, advanced imaging, invasive or noninvasive hemodynamics, human-derived specimens, biomarker validation, or other translational approaches that directly evaluate relevance in people.
What NIH policy areas should applicants be prepared to address because human subjects research is required?
Applicants should be prepared to align with NIH human subjects policies and address typical patient-oriented research considerations, including human subjects protections, study design, recruitment, and related regulatory and ethical requirements.
What is the grant mechanism for this opportunity?
The mechanism is an NIH R01 research project grant.
What is the estimated total funding level and the maximum award size?
The estimated total funding level is listed as $4,050,000. The award ceiling (maximum size for a single award under the announcement) is $450,000.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement.
What is the program area and which CFDA numbers are associated with it?
The opportunity is categorized under Health and is associated with CFDA 93.837 (Cardiovascular Diseases Research) and 93.838 (Lung Diseases Research).
When was this opportunity posted and what were the closing dates?
The opportunity was posted on April 5, 2011. The original and current closing date listed is October 13, 2011. It was archived on November 13, 2011.
Who is eligible to apply?
Eligibility is broad. Eligible applicants include various levels of government (federal, state, county, city/township), special district governments, independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, nonprofits (with or without 501(c)(3) status, including those other than institutions of higher education), for-profit organizations (including small businesses), and public housing authorities/Indian housing authorities.
Are specific institution types and community-based organizations included in eligibility?
Yes. The FOA includes Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and certain tribal organizations and governments (including some categories that note tribal entities not federally recognized).
Can non-U.S. (foreign) organizations apply?
Yes. The announcement allows non-U.S. entities (foreign organizations) to apply, and it also allows foreign components of U.S. organizations. This supports international collaboration or international recruitment as long as the project fits NIH rules and the FOA requirements.
What is the overall purpose or expected impact of this program?
The program aims to accelerate progress on understanding and treating RV dysfunction and failure that occur in pulmonary vascular disease, a high clinical-need area. By requiring human subjects research and encouraging multi-PI, team-based approaches, it is structured to promote clinically meaningful, translational work connecting mechanisms to improved diagnostics and therapeutics.
Where can applicants find the official announcement?
The source is the NIH Grants Guide page for RFA-HL-12-021, which contains the full official announcement and any detailed requirements beyond this summary.
Browse more opportunities from the same category: Health
Next opportunity: Short Term Institutional Training Grant for Clinician Scientists in Pediatric Respiratory, Sleep and Hematology/Transfusion Medicine (T35)
Previous opportunity: Basic Research in Calcific Aortic Valve Disease (R01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA HL 12 021
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA HL 12 021) also looked into and applied for these:
| Funding Opportunity |
|---|
| Short Term Institutional Training Grant for Clinician Scientists in Pediatric Respiratory, Sleep and Hematology/Transfusion Medicine (T35) Apply for RFA HL 12 017 Funding Number: RFA HL 12 017 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pathophysiology of HIV Associated Neurodegeneration in Aging Populations on Long Term Anti Retroviral Therapy (R01) Apply for RFA MH 12 070 Funding Number: RFA MH 12 070 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pathophysiology of HIV Associated Neurodegeneration in Aging Populations on Long Term Anti Retroviral Therapy (R21) Apply for RFA MH 12 071 Funding Number: RFA MH 12 071 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| 2011 Announcement of Availability of Funds for One Cooperative Agreement to Publish Public Health Reports Apply for SG PHR 11 001 Funding Number: SG PHR 11 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: Case Dependent |
| Planning Grants for Expansion of the Comprehensive Community Mental Health Services for Children and their Families Apply for SM 11 008 Funding Number: SM 11 008 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $800,000 |
| Allergen Epitope Research and Validation Cnters (U19) Apply for RFA AI 11 013 Funding Number: RFA AI 11 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition The Health and Retirement Study (U01) Apply for RFA AG 12 001 Funding Number: RFA AG 12 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global Health Fellows Program II (GHFP II) Apply for SOL OAA 11 000042 Funding Number: SOL OAA 11 000042 Agency: Agency for International Development Category: Health Funding Amount: $220,000,000 |
| Improving Child and Maternal Nutrition in Tanzania Apply for USAID TANZAIA 11 005 RFA Funding Number: USAID TANZAIA 11 005 RFA Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $35,000,000 |
| Life After Linkage The Future of Family Studies (R01) Apply for RFA HL 12 007 Funding Number: RFA HL 12 007 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Understanding Clinical Information Needs and Health Care Decision Making Processes in the Context of Health Information Technology (IT) (R01) Apply for PA 11 198 Funding Number: PA 11 198 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Academic Career Award (Parent K07) Apply for PA 11 192 Funding Number: PA 11 192 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders Apply for CDC RFA DD11 1103 Funding Number: CDC RFA DD11 1103 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Understanding User Needs and Context to Inform Consumer Health Information Technology (IT) Design (R01) Apply for PA 11 199 Funding Number: PA 11 199 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Services Grant Program for Residential Treatment for Pregnant and Postpartum Women Apply for TI 11 009 Funding Number: TI 11 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $524,000 |
| Grants to Enhance Older Adult Behavioral Health Services Apply for SM 11 009 Funding Number: SM 11 009 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $356,344 |
| Cooperative Agreement for the Drug Demand Reduction Initiative for Iraq Apply for TI 11 011 Funding Number: TI 11 011 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $770,000 |
| Service Area Competition Additional Areas Apply for HRSA 11 178 Funding Number: HRSA 11 178 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,072,582 |
| NIMHD Health Disparities Research (R01) Apply for RFA MD 12 001 Funding Number: RFA MD 12 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Cooperative Agreement with the Supply Chain Management System (SCMS) Apply for CDC RFA GH11 11106 Funding Number: CDC RFA GH11 11106 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA HL 12 021", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.